Posted by Michael Wonder on 29 Jun 2024
Highlights from the 24-27 June 2024 CHMP meeting
28 June 2024 - The EMA’s CHMP recommended ten medicines for approval at its June 2024 meeting.
The committee recommended granting a marketing authorisation for Balversa (erdafitinib), for the treatment of adult patients with unresectable or metastatic urothelial carcinoma, a cancer of the bladder and urinary system.
